Oseltamivir — Discount Pricing

Other medications in Infections

• Penicillin VK
• Polymyxin B
• Pyrazinamide
• Raltegravir
• Rifampin
• Rilpivirine
• Sofosbuvir
• Tedizolid

What Oseltamivir is approved for (FDA label)

Oseltamivir phosphate capsules are an influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. (1.1) Prophylaxis of influenza A and B in patients 1 year and older. (1.2) Limitations of Use: Not a substitute for annual influenza vaccination. (1.3) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. (1.3) Not recommended for patients with end-stage renal disease not undergoing dialysis. (1.3) 1.1 Treatment of Influenza Oseltamivir phosphate capsules are indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. 1.2 Prophylaxis of Influenza Oseltamivir phosphate capsules are indicated for the prophylaxis of influenza A and B in patients 1 year and older. 1.3 Limitations of Use Oseltamivir phosphate capsules are not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices.

Source: Read the full FDA label on DailyMed. Label effective date: January 15, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Oseltamivir (FDA label)

Oseltamivir Phosphate Capsules, USP: 30-mg (30 mg free base equivalent of the phosphate salt): Hard gelatin capsules with yellow ivory opaque cap and yellow ivory opaque body printed “AMNEAL” on cap and “264” on body with blue ink. 45-mg (45 mg free base equivalent of the phosphate salt): Hard gelatin capsules with light gray opaque cap and light gray opaque body printed “AMNEAL” on cap and “265” on body with blue ink. 75-mg (75 mg free base equivalent of the phosphate salt): Hard gelatin capsules with yellow ivory opaque cap and light gray opaque body printed “AMNEAL” on cap and “266” on body with blue ink. Capsules: 30 mg, 45 mg, 75 mg (3)

Source: FDA prescribing information (DailyMed). Set ID: c61bb5af-558f-4b32-b34d-8fdae480443c. SPL document ID: 487151fd-29d3-da81-e063-6394a90a2d8f. Label effective date: January 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Oseltamivir (FDA label)

The following serious adverse reactions are discussed below and elsewhere in the labeling: Serious skin and hypersensitivity reactions [see Warnings and Precautions (5.1) ] Neuropsychiatric events [see Warnings and Precautions (5.2) ] Most common adverse reactions (> 1% and more common than with placebo): Treatment studies – Nausea, vomiting, headache. (6.1) Prophylaxis studies – Nausea, vomiting, headache, pain. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact AvKARE, Inc. at 1-855-361-3993 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: c61bb5af-558f-4b32-b34d-8fdae480443c. SPL document ID: 487151fd-29d3-da81-e063-6394a90a2d8f. Label effective date: January 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.